Seagen Valuation
Is SGEN * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SGEN * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SGEN * (MX$3711.48) is trading above our estimate of fair value (MX$3007.4)
Significantly Below Fair Value: SGEN * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SGEN *?
Other financial metrics that can be useful for relative valuation.
What is SGEN *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$35.91b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 16.8x |
Enterprise Value/EBITDA | -58.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SGEN *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 8.7x | ||
MRNA Moderna | 5.8x | 13.6% | US$40.3b |
A068270 Celltrion | 16.4x | 19.3% | ₩37.0t |
BNTX BioNTech | 5.2x | 2.3% | US$20.8b |
HZNP Horizon Therapeutics | 7.3x | 8.3% | US$26.6b |
SGEN * Seagen | 17.5x | 23.1% | Mex$35.9b |
Price-To-Sales vs Peers: SGEN * is expensive based on its Price-To-Sales Ratio (17.5x) compared to the peer average (7.4x).
Price to Earnings Ratio vs Industry
How does SGEN *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: SGEN * is expensive based on its Price-To-Sales Ratio (17.5x) compared to the Global Biotechs industry average (9.6x).
Price to Sales Ratio vs Fair Ratio
What is SGEN *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 17.5x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate SGEN *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.